“We saw that with each additional enrichment feature the odds of finding a germline mutation would double,” says Alexis Rompré-Brodeur, MD.
Alexis Rompré-Brodeur, MD, a urologic oncologist at McGill University discusses results of the study, “Germline testing in renal cell carcinoma: can enrichment features help predict germline alterations?” which he presented at the 2022 AUA Annual Meeting (PD18-10).
Grant to fund research on biomarkers for toxicity from prostate cancer radiation
July 11th 2024“By understanding the mirSNP genetic markers that predispose patients to adverse side effects from cancer therapy we can tailor these therapies to minimize harm and maximize efficacy," says Joanne B. Weidhaas, MD, PhD, MS.
Gene-expression signature could serve as biomarker for recurrence in ccRCC
June 26th 2024“Even when we adjusted for other clinical variables, like age or grade of tumor, this signature was still independently associated with recurrence after treatment for this form of kidney cancer," says Simpa S. Salami, MD, MPH.